Cochrane · systematic review · CD010758
Vilanterol and fluticasone furoate for asthma
Dwan, K, Milan, SJ, Bax, L, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 5 · 71.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vilanterol and fluticasone furoate compared with placebo for asthma
Population: people with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Health‐related quality of life Vilanterol and fluticasone furoate vs placebo | MD 0.3 | 2012 participants | Moderate |
Asthma exacerbation Vilanterol and fluticasone furoate vs placebo | no estimate extracted | 2 studies · 2013 participants | Very low |
Serious adverse events Vilanterol and fluticasone furoate vs placebo | no estimate extracted | 2013 participants | Very low |
FEV1 Vilanterol and fluticasone furoate vs placebo | MD 0.17 | 1 study · 100 participants | Moderate |
Peak expiratory flow Vilanterol and fluticasone furoate vs placebo | MD 33.3 | 2012 participants | Moderate |
Asthma symptoms Vilanterol and fluticasone furoate vs placebo | MD 17.9 | 1 study · 2012 participants | Moderate |
Adverse events Vilanterol and fluticasone furoate vs placebo | no estimate extracted | 8 participants | Moderate |